Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

41 results about "Daytime somnolence" patented technology

Somnolence is often viewed as a symptom rather than a disorder by itself. However, the concept of somnolence recurring at certain times for certain reasons constitutes various disorders, such as excessive daytime sleepiness, shift work sleep disorder, and others; and there are medical codes for somnolence as viewed as a disorder.

Modified release compositions of milnacipran

A once-a-day oral milnacipran modified release formulation has been developed. The formulation comprises an extended release dosage unit (optionally containing the immediate release portion) coated with delayed release coating. The milnacipran composition, when administered orally, first passes through the stomach releasing from zero to less than 10% of the total milnacipran dose and then enters the intestines where drug is released slowly over an extended period of time. The release profile is characterized by a 0.05-4 hours lag time period during which less than 10% of the total milnacipran dose is released followed by a slow or extended release of the remaining drug over a defined period of time. The composition provides in vivo drug plasma levels characterized by Tmax at 4-10 hours and an approximately linear drop-off thereafter and Cmax below 3000 ng / ml, preferably below 2000 ng / ml, and most preferably below 1000 ng / ml. The composition allows milnacipran to be delivered over approximately 24 hours, when administered to a patient in need, resulting in diminished incidence or decreased intensity of common milnacipran side effects such as sleep disturbance, nausea, vomiting, headache, tremulousness, anxiety, panic attacks, palpitations, urinary retention, orthostatic hypotension, diaphoresis, chest pain, rash, weight gain, back pain, constipation, vertigo, increased sweating, agitation, hot flushes, tremors, fatigue, somnolence, dyspepsia, dysoria, nervousness, dry mouth, abdominal pain, irritability, and insomnia.
Owner:COLLEGIUM PHARMA INC

Pulsatile release compositions of milnacipran

InactiveUS20060003004A1Minimize exposureReduces milnacipran gastrointestinal side effectCapsule deliveryCoatingsPalpitationsPanic
A once-a-day oral milnacipran pulsatile release composition has been developed that releases the drug in spaced apart “pulses”. The dosage forms are comprised of first, second and optional third dosage units, with each dosage unit having a different drug release profile. This dosage form provides in vivo drug plasma levels characterized by Cmax below 3000 ng / ml, preferably below 2000 ng / ml, and most preferably below 1000 ng / ml. The composition provides pulsatile release of milnacipran to produce a therapeutic effect over approximately 24 hours, when administered to a patient in need, resulting in diminished incidence or decreased intensity of common milnacipran side effects such as sleep disturbance, nausea, vomiting, headache, tremulousness, anxiety, panic attacks, palpitations, urinary retention, orthostatic hypotension, diaphoresis, chest pain, rash, weight gain, back pain, constipation, vertigo, increased sweating, agitation, hot flushes, tremors, fatigue, somnolence, dyspepsia, dysoria, nervousness, dry mouth, abdominal pain, irritability, and insomnia.
Owner:COLLEGIUM PHARMA INC

Compositions and methods for enhancing analgesic potency of covalently bound-compounds, attenuating its adverse side effects, and preventing their abuse

InactiveUS20100144645A1Lower potentialAmenable to synthesizing conjugatesBiocideNervous disorderChemical MoietyOpioid antagonist
The invention generally relates to compositions and methods with covalently bound compounds, such as controlled substances covalently attached to a chemical moiety, and opioid antagonists or covalently bound opioid antagonists to enhance analgesic potency and/or attenuate one or more adverse effects of covalently bound compounds, including adverse side effect(s) in humans such as nausea, vomiting, dizziness, headache, sedation (somnolence), physical dependence or pruritis. This invention relates to compositions and methods for selectively enhancing the analgesic potency of a covalently bound compound and simultaneously attenuating anti-analgesia, hyperalgesia, hyperexcitability, physical dependence and/or tolerance effects associated with the administration of a covalently bound compound. The methods of the invention comprise administering to a subject an analgesic or sub-analgesic amount of a covalently bound compound and an amount of excitatory opioid receptor antagonist such as naltrexone or nalmefene effective to enhance the analgesic potency of a covalently bound compound and attenuate the anti-analgesia, hyperalgesia, hyperexcitability, physical dependence and/or tolerance effects of covalently bound compound. The invention also relates to the addition of covalently-bound opioid antagonists to the compositions containing covalently bound compounds such that if the compositions are subjected to manipulation by illicit chemists, the opioid antagonist is released effectively reducing or eliminating the euphoric effect of the covalently bound compounds.
Owner:SHIRE PLC

CNS pharmaceutical compositions and methods of use

The present invention is directed to CNS pharmaceutical compositions and methods of use. The pharmaceutical compositions comprise a CNS active agent and preferably at least two vagal neuromodulators, one of which is a mechanoreceptor stimulator. The vagal neuromodulators are preferably in an amount sufficient to reduce a somnolence side-effect of the CNS active agent without changing its therapeutic efficacy / activity. The invention further encompasses a method of reducing CNS active agent side-effects. The method typically comprises oral administration of at least one CNS active agent to a patient at the conventionally accepted dose; and administration of at least two vagal neuromodulators to the patient so that at least one neuromodulator is administered or released from dosage form after the CNS active agent is administered and / or released.
Owner:TARGIA PHARMA

Chinese medicinal composition for curing somnolence and preparation method thereof

The invention discloses a novel Chinese medicinal composition for curing somnolence and a preparation method thereof. The Chinese medicinal composition mainly comprises the following raw material medicaments: tangerine peel, immature bitter orange, raw raidx astragali, white paeony root, Chinese angelica, common yam rhizome, campanumaea pilosula, ginseng, motherwort herb, storax, nutgrass galingale rhizome, camphor, Szechwan Chinaberry Fruit, chrysanthemum, salvia miltiorrhiza bunge, fineleaf schizonepeta herb, divaricate saposhnikovia root, incised notopterygium rhizome, medicated leaven, malt, radish seed, peach seed, safflower, south dodder seed, twotooth achyranthes root and the like. The Chinese medicinal composition can be prepared into any common oral preparation by the conventional Chinese medicinal preparation method. The Chinese medicinal composition can obviously improve symptoms such as somnolence, drowsiness, cataplexy, sleep paralysis, hypnoagogic hallucination and the like. The Chinese medicinal composition has the advantages of exact clinical effect, obvious curative effect, quick response, low cost, basically no toxic or side effect and the like because the Chinese medicinal composition is basically combined by edible and pharmaceutical medicaments specified in national formulary.
Owner:TAIYI HEPU BEIJING RES INST OF TCM

Medicine for clearing heat and calming nerves and preparation method thereof

The invention relates to a Chinese herbal medicine, in particular to a medicine for clearing heat and calming nerves and a preparation method thereof. The medicine comprising the following ingredients: 5-30 weight portions of polygala root, 5-30 weight portions of amber, 5-40 weight portions of oyster, 1-15 weight portions of magnetite (calcined), 5-30 weight portions of Chinese magnoliavine, 1-15 weight portions of Ligusticum wallichii, 5-30 weight portions of chrysanthemum, 5-30 weight portions of Chinese angelica, 5-40 weight portions of keel (calcined), 5-30 weight portions of irkutsk anemone rhizome, 5-30 weight portions of rehmannia glutinosa, 5-30 weight portions of salvia miltiorrhiza, 5-30 weight portions of tuber of dwarf lilyturf, 1-15 weight portions of licorice, 5-40 weight portions of polygonatum odoratum, 5-30 weight portions of cape jasmine, 5-20 weight portions of scutellaria baicalensis, 1-15 weight portions of vine of multiflower knotweed, and 1-15 weight portions of Celastrus orbiculatus Thunb. The medicine disclosed in the invention processed by extraction and purification has high medicine component contents, little medicine dosage and strict quality control indexes, and achieves the requirements of safety and efficiency, controllable quality and convenient taking. The medicine provided by the invention can be taken for a long time without adverse reactions of listlessness, absentmindedness, somnolence and the like.
Owner:LIAONING HUAXIN PHARMA

Traditional Chinese medicine health tea

InactiveCN108029819ANormal metabolismWith qi and depressionTea substituesSide effectAdditive ingredient
The invention discloses traditional Chinese medicine health tea. The traditional Chinese medicine health tea is prepared from the following raw materials in parts by weight: 50-70 parts of roses, 50-70 parts of jasmine flowers, 50-70 parts of seville orange flowers, 50-70 parts of lotus leaves, 30-50 parts of wolfberry fruits and 5-20 parts of dried orange peel. The traditional Chinese medicine health tea adopts common medicinal and edible traditional Chinese medicines as raw materials, is safe and reliable, has no toxic and side effects and no injury to the digestive system and the absorptionsystem of a human body, can give full play to medicinal effects of every traditional Chinese medicine component by compatible application of the raw materials and has the efficacies of beautifying skin, reducing lipid, producing a refreshing effect, regulating the flow of qi, relieving stagnation, resolving phlegm and removing dampness by diuresis. Honey in the traditional Chinese medicine healthtea is mainly used for flavoring and added on the preference of drinkers. The traditional Chinese medicine health tea is capable of promoting normal metabolism of a human body, has obvious weight reducing effects and also has good efficacies of regulating the flow of qi, relieving stagnation, resolving phlegm and removing dampness by diuresis on patients who have fatty liver disease due to accumulation of phlegm-dampness in the body and have the following clinical manifestations: fat body, dull pain in chest and hypochondrium, dizziness, choking sensation in chest, somnolence, tiredness and the like.
Owner:河南明珍方医药科技有限公司

Middle-aged and elderly health-care food for improving sleep and protecting eyesight and preparation method thereof

The invention belongs to the technical field of food, and in particular relates to a middle-aged and elderly health-care food for improving sleep and protecting eyesight and a preparation method thereof. The formula of the middle-aged and elderly health-care food for improving sleep and protecting eyesight comprises the following components by weight percent: 5-10 percent of xanthophyll, 20-50 percent of Ganoderma atrum extract, 1-5 percent of melatonin and 20-50 percent of grassleaf sweelflag rhizome extract. The formula is scientific and reasonable, has the functions of calming the mind and nerves, relieving anxiety, promoting sleep, and improving sleep quality, and can not cause dizzness, somnolence and addiction which are caused by common drugs after awaking. In addition, the health-care food also has the effects of relieving asthenopia and hypopsia caused by insomnia, improving blurred vision and protecting the eyesight.
Owner:南京贝杉国际贸易有限公司

Traditional Chinese medicine for treating damp-abundance spleen trapped type somnolence disease

The invention relates to the field of traditional Chinese medicine, in particular to a traditional Chinese medicine for treating a damp-abundance spleen trapped type somnolence disease. The traditional Chinese medicine is prepared from 10-20 g of Chinese yams, 10-20 g of medcinal evodia fruit, 8-18 g of Chinese starjasmine stems, 8-18 g of fiveleaf gynostemma herb, 8-18 g of semen coicis, 8-18 g of gorgon euryale seeds, 8-18 g of radix stephaniae tetrandrae, 8-18 g of officinal magnolia bark, 8-18 g of rhizoma atractylodis macrocephalae, 8-18 g of prepared common monkshood daughter roots, 5-15 g of cortex erythrinae, 5-15 g of poria cocos, 5-15 g of heterophyllous wing seedtree roots, 5-15 g of paniculate swallowwort roots, 3-9 g of cocklebur fruit, 2-10 g of radix codonopsis, 2-10 g of java amomum fruit, 2-10 g of pericarpium citri reticulatae, 2-10 g of licorice roots, 2-10 g of cortex cinnamomi and 2-10 g of ginger. According to clinical experiments, the cure rate of the traditional Chinese medicine for treating the damp-abundance spleen trapped type somnolence disease is high than 96.92 percent and can reach up to 99.23 percent, the average cure rate is 98.15 percent, the total effective rate is 100 percent, and the traditional Chinese medicine is very suitable for treating the damp-abundance spleen trapped type somnolence disease. In addition, the traditional Chinese medicine is quick in efficacy, short in cure cycle, and the traditional Chinese medicine composition is prepared from pure traditional Chinese medicines and is free of toxic and side effects and free of concerns about the drug dependence.
Owner:JINAN SHUNXIANG MEDICINE SCI & TECH

Traditional Chinese medicine for treating liver stagnation and spleen deficiency type post-stroke depression

The invention relates to a traditional Chinese medicine for treating liver constraint and spleen deficiency type post-stroke depression. The traditional Chinese medicine has obvious treatment effects on symptoms such as deprementia, chest hypochondriac pain, lassitude, upset irritability, abdominal distension and diarrhea and the like of the liver constraint and spleen deficiency type post-strokedepression, improves spirit and emotions, promotes the recovery of neural functions of stroke patients, and does not have obvious toxic or side effects such as dizziness, hypodynamia, somnolence, drymouth, constipation, hypotension, abnormal liver functions, epilepsy, cardiac arrhythmia, toxicosis and the like. The technical scheme is that: the traditional Chinese medicine is prepared form the following raw materials by weight: 10 to 14g of bupleurum, 9 to 11g of turmeric root-tuber, 10 to 14g of Chinese angelica, 10 to 14g of white paeony root, 13.5 to 16.5g of fried largehead atractylodes rhizome, 9 to 11g of Indian buead, 18 to 22g of codonopsis pilosula, 9 to 11g of tangerine peel, 9 to 11g of bamboo shavings, 13.5 to 16.5g of gardenia, 4.5 to 5.5g of mint and 2.7 to 3.3g of liquoricroot. The traditional Chinese medicine is prepared into decoction by the conventional soaking, decocting and filtering or is prepared by directly blending market-sold single Chinese medicinal formulaparticles. The traditional Chinese medicine has the advantages of high reliability, high safety, high flexibility, no dependence and the like.
Owner:HENAN UNIV OF CHINESE MEDICINE

Traditional Chinese medicine for treating somnolence caused by yang-qi deficiency

The invention relates to the field of traditional Chinese medicine, in particular to a traditional Chinese medicine for treating somnolence caused by yang-qi deficiency. The traditional Chinese medicine is prepared from 10-20 g of cynomorium songaricum, 10-20 g of evodia, 8-18 g of cibotium barometz, 8-18 g of epimedium, 8-18 g of coix seeds, 8-18 g of gordon euryale seeds, 8-18 g of curculigo orchioides, 8-18 g of radix astragali preparata, 8-18 g of rhizoma chuanxiong, 8-18 g of radix aconite lateralis preparata, 5-15 g of aralia chinensis L., 5-15 g of poria cocos, 5-15 g of astragalus complanatus bunge, 5-15 g of radix cynanchi panicullati, 3-9 g of fructus xanthii, 2-10 g of radix codonopsis, 2-10 g of atractylodes macrocephala koidz, 2-10 g of tangerine peel, 2-10 g of liquorice, 2-10 g of lindera aggregate and 2-10 g of dried ginger. Clinical experiments for treating somnolence caused by yang-qi deficiency show that the cure rate is higher than 95.24% and can reach 99.21% at most, the average cure rate is 97.46%, the total effective rate is 100%, and the traditional Chinese medicine is quite suitable for treating somnolence caused by yang-qi deficiency. In addition, the traditional Chinese medicine is quick in effect and short in cure period, is prepared from pure traditional Chinese machine, and is free of toxic and side effects and free of worries of medicine dependence.
Owner:JINAN SHUNXIANG MEDICINE SCI & TECH

Traditional Chinese medicine for treating blood stasis type somnolence

The invention relates to the field of traditional Chinese medicines, and in particular relates to a traditional Chinese medicine for treating blood stasis type somnolence. The traditional Chinese medicine is prepared from the following components by weight: 10-20 g of caulis spatholobi, 10-20 g of radix puerariae, 8-18 g of myrrh, 8-18 g of frankincense, 8-18 g of dalbergia wood, 8-18 g of the root bark of the peony tree, 8-18 g of beautiful sweetgum fruits, 8-18 g of curcuma zedoary, 5-15 g of the seeds of cowherb, 5-15 g of radix curcumae longae, 5-15 g of radix paeoniae rubra, 5-15 g of cassia twig, 5-15 g of radix bupleuri, 5-15 g of hematoxylon, 2-10 g of musk, 2-10 g of clove, 2-10 g of peach kernels, 2-10 g of Armeniaca mume, 2-10 g of radish seeds, 2-10 g of chastetree fruits, 2-10 g of gentiana macrophylla, 2-10 g of salsola ruthenica, 2-10 g of hematoxylon, and 2-10 g of rhizoma chuanxiong. The traditional Chinese medicine has the cure rate higher than 95.35% for the blood stasis type somnolence proved through clinical experiment, the highest cure rate is 100%, the average cure rate is 97.91%, the total effective rate is 100%, and the traditional Chinese medicine is very suitable for treating the blood stasis type somnolence, rapid in taking effect, and short in cure cycle; the traditional Chinese medicine composition is prepared from pure traditional Chinese medicinal materials, is free of toxic and side effects, and is free of the trouble of drug dependence.
Owner:JINAN SHUNXIANG MEDICINE SCI & TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products